Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2012, Pages

  Oleaga, Carlota ^a   Ciudad, Carlos J ^a   Noé, Véronique ^a   Izquierdo Pulido, Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER CELLS; CAFFEIC ACIDS; CANCER CELLS; CHEMOPREVENTIVE EFFECTS; COFFEE CONSUMPTION; COLON CANCER CELLS; CYCLIND1; DIFFERENTIALLY EXPRESSED GENE; EPIDEMIOLOGICAL STUDIES; EXPERIMENTAL CONDITIONS; INTERCONNECTED NODES; MOLECULAR MECHANISM; MRNA LEVEL; OVER-EXPRESSION; POLYPHENOLS; PROTEIN LEVEL; TARGET GENES;

GENES; PHENOLS;

CELLS;

ACTIVATING TRANSCRIPTION FACTOR 2; CAFFEIC ACID; CYCLIN D1; MESSENGER RNA; POLYPHENOL; STAT5B PROTEIN; ATF2 PROTEIN, HUMAN; CAFFEIC ACID DERIVATIVE; CAFFEINE; CCND1 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COFFEE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG TARGETING; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE; TUMOR GENE;

ACTIVATING TRANSCRIPTION FACTOR 2; CAFFEIC ACIDS; CAFFEINE; CELL LINE, TUMOR; COFFEE; CYCLIN D1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; NEOPLASMS; POLYPHENOLS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; STAT5 TRANSCRIPTION FACTOR;

EID: 84866164298     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2012/390385     Document Type: Article

References (89)

1. Scalbert A., Manach C., Morand C., Rémésy C., Jiménez L., Dietary polyphenols and the prevention of diseases. Critical Reviews in Food Science and Nutrition 2005 45 4 287 306 2-s2.0-14744302388 10.1080/1040869059096 (Pubitemid 41657352)
2. Scalbert A., Johnson I. T., Saltmarsh M., Polyphenols: antioxidants and beyond. The American Journal of Clinical Nutrition 2005 81 1 215S 217S 2-s2.0-13844255694
3. Azzi A., Davies K. J., Kelly F., Free radical biologyterminology and critical thinking. FEBS Letters 2004 558 13 3 6 2-s2.0-0842346333 10.1016/S0014-5793(03)01526-6 (Pubitemid 38167400)
4. Halliwell B., Rafter J., Jenner A., Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? The American Journal of Clinical Nutrition 2005 81 1 268S 276S 2-s2.0-13844298231
5. Olthof M. R., Hollman P. C., Katan M. B., Chlorogenic acid and caffeic acid are absorbed in humans. Journal of Nutrition 2001 131 1 66 71 2-s2.0-0035176633 (Pubitemid 32060624)
6. Olthof M. R., Hollman P. C., Buijsman M. N., van Amelsvoort J. M., Katan M. B., Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. Journal of Nutrition 2003 133 6 1806 1814 2-s2.0-0037977138 (Pubitemid 36666517)
7. Rice-Evans C. A., Miller N. J., Paganga G., Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biology and Medicine 1996 20 7 933 956 2-s2.0-0029888128 10.1016/0891-5849(95)02227-9 (Pubitemid 26157509)
8. Kono Y., Shibata H., Kodama Y., Sawa Y., The suppression of the N-nitrosating reaction by chlorogenic acid. The Biochemical Journal 1995 312, part 3 947 953 2-s2.0-0029561410 (Pubitemid 26006011)
9. Shibata H., Sakamoto Y., Oka M., Kono Y., Natural antioxidant, chlorogenic acid, protects against DNA breakage caused by monochloramine. Bioscience, Biotechnology and Biochemistry 1999 63 7 1295 1297 2-s2.0-0033159195 (Pubitemid 129549093)
10. Kasai H., Fukada S., Yamaizumi Z., Sugie S., Mori H., Action of chlorogenic acid in vegetables and fruits as an inhibitor of 8-hydroxydeoxyguanosine formation in vitro and in a rat carcinogenesis model. Food and Chemical Toxicology 2000 38 5 467 471 2-s2.0-0034070596 10.1016/S0278-6915(00)00014-4 (Pubitemid 30179737)
11. Feng R., Lu Y., Bowman L. L., Qian Y., Castranova V., Ding M., Inhibition of activator protein-1, NF- κ B, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. The Journal of Biological Chemistry 2005 280 30 27888 27895 2-s2.0-23044442718 10.1074/jbc.M503347200 (Pubitemid 41076906)
12. Larsson S. C., Wolk A., Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007 132 5 1740 1745 2-s2.0-34247633571 10.1053/j.gastro.2007.03.044 (Pubitemid 46677953)
13. Bravi F., Bosetti C., Tavani A., Bagnardi V., Gallus S., Negri E., Franceschi S., La Vecchia C., Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007 46 2 430 435 2-s2.0-34548297395 10.1002/hep.21708 (Pubitemid 47344778)
14. Je Y., Liu W., Giovannucci E., Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. International Journal of Cancer 2009 124 7 1662 1668 2-s2.0-61449253081 10.1002/ijc.24124
15. Tang N., Zhou B., Wang B., Yu R., Coffee consumption and risk of breast cancer: a metaanalysis. American Journal of Obstetrics and Gynecology 2009 200 3 290.e1 290.e9 2-s2.0-60849128495 10.1016/j.ajog.2008.10.019
16. Naganuma T., Kuriyama S., Kakizaki M., Sone T., Nakaya N., Ohmori-Matsuda K., Nishino Y., Fukao A., Tsuji I., Coffee consumption and the risk of oral, pharyngeal, and esophageal cancers in Japan: the Miyagi Cohort Study. American Journal of Epidemiology 2008 168 12 1425 1432 2-s2.0-57849115829 10.1093/aje/kwn282
17. Wilson K. M., Kasperzyk J. L., Rider J. R., Kenfield S., Van Dam R. M., Stampfer M. J., Giovannucci E., Mucci L. A., Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. Journal of the National Cancer Institute 2011 103 11 876 884 2-s2.0-79958816207 10.1093/jnci/djr151
18. Nkondjock A., Coffee consumption and the risk of cancer: an overview. Cancer Letters 2009 277 2 121 125 2-s2.0-62749184366 10.1016/j.canlet.2008.08. 022
19. Ganmaa D., Willett W. C., Li T. Y., Feskanich D., Van Dam R. M., Lopez-Garcia E., Hunter D. J., Holmes M. D., Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. International Journal of Cancer 2008 122 9 2071 2076 2-s2.0-40749161601 10.1002/ijc.23336 (Pubitemid 351441198)
20. Li J., Seibold P., Chang-Claude J., Flesch-Janys D., Liu J., Czene K., Humphreys K., Hall P., Coffee consumption modifies risk of estrogen-receptor negative breast cancer. Breast Cancer Research 2011 13 3, article R49 2-s2.0-79955761091 10.1186/bcr2879
21. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983 65 1-2 55 63 2-s2.0-0021061819 (Pubitemid 14203433)
22. Selga E., Oleaga C., Ramírez S., de Almagro M. C., Noé V., Ciudad C. J., Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Medicine 2009 1 9, article 83 2-s2.0-77953413882 10.1186/gm83
23. Selga E., Morales C., Noe V., Peinado M. A., Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Medical Genomics 2008 1, article 35
24. Gillett C. E., Lee A. H., Millis R. R., Barnes D. M., Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. The Journal of Pathology 1998 184 396 400
25. Buckley M. F., Sweeney K. J., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., DeFazio A., Watts C. K. W., Musgrove E. A., Sutherland R. L., Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993 8 8 2127 2133 2-s2.0-0027280084 (Pubitemid 23226946)
26. Lim E. J., Joung Y. H., Jung S. M., Park S. H., Park J. H., Kim S. Y., Hwang T. S., Hong D. Y., Chung S. C., Ye S. K., Moon E. S., Park E. U., Park T., Chung I. M., Yang Y. M., Hemin inhibits cyclin D1 and IGF-1 expression via STAT5b under hypoxia in ER α -negative MDA-MB 231 breast cancer cells. International Journal of Oncology 2010 36 5 1243 1251 2-s2.0-77950425377 10.3892/ijo-00000608
27. Joung Y. H., Lim E. J., Kim M. S., Lim S. D., Yoon S. Y., Lim Y. C., Yoo Y. B., Ye S. K., Park T., Chung I. M., Bae K. Y., Yang Y. M., Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B. International Journal of Oncology 2008 33 3 477 484 2-s2.0-54849187900 10.3892/ijo00000030
28. Fox E. M., Bernaciak T. M., Wen J., Weaver A. M., Shupnik M. A., Silva C. M., Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Molecular Endocrinology 2008 22 8 1781 1796 2-s2.0-48249132499 10.1210/me.2007-0419
29. Lange C. A., Richer J. K., Shen T., Horwitz K. B., Convergence of progesterone and epidermal growth factor signaling in breast cancer: potentiation of mitogen-activated protein kinase pathways. The Journal of Biological Chemistry 1998 273 47 31308 31316 2-s2.0-0032553304 10.1074/jbc.273.47.31308 (Pubitemid 28533147)
30. Beier F., Lee R. J., Taylor A. C., Pestell R. G., Luvalle P., Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. Proceedings of the National Academy of Sciences of the United States of America 1999 96 4 1433 1438 2-s2.0-0033573913 10.1073/pnas.96.4.1433 (Pubitemid 29098468)
31. Sabbah M., Courilleau D., Mester J., Redeuilh G., Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 11217 11222 2-s2.0-0033613085 10.1073/pnas.96.20.11217 (Pubitemid 29487361)
32. Lewis J. S., Thomas T. J., Pestell R. G., Albanese C., Gallo M. A., Thomas T., Differential effects of 16 α -hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. Journal of Molecular Endocrinology 2005 34 1 91 105 2-s2.0-14544273363 10.1677/jme.1.01599 (Pubitemid 40305552)
33. Wakao H., Gouilleux F., Groner B., Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO Journal 1994 13 9 2182 2191 2-s2.0-0028217452 (Pubitemid 24139732)
34. Hou J., Schindler U., Henzel W. J., Wong S. C., McKnight S. L., Identification and purification of human stat proteins activated in response to interleukin-2. Immunity 1995 2 4 321 329 2-s2.0-0028964916
35. Liu X., Robinson G. W., Gouilleux F., Groner B., Hennighausen L., Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proceedings of the National Academy of Sciences of the United States of America 1995 92 19 8831 8835 2-s2.0-0029115640 10.1073/pnas.92.19.8831
36. Lin J. X., Mietz J., Modi W. S., John S., Leonard W. J., Cloning of human Stat5B: reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. The Journal of Biological Chemistry 1996 271 18 10738 10744 2-s2.0-15844386904 10.1074/jbc.271.18.10738 (Pubitemid 26145810)
37. Mui A. L., Wakao H., O'Farrell A. M., Harade N., Miyajima A., Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO Journal 1995 14 6 1166 1175 2-s2.0-0028963550
38. Udy G. B., Towers R. P., Snell R. G., Wilkins R. J., Park S. H., Ram P. A., Waxman D. J., Davey H. W., Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proceedings of the National Academy of Sciences of the United States of America 1997 94 14 7239 7244 2-s2.0-0030833570 10.1073/pnas.94.14.7239 (Pubitemid 27345299)
39. Teglund S., McKay C., Schuetz E., Van Deursen J. M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., Ihle J. N., Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998 93 5 841 850 2-s2.0-0000943469 10.1016/S0092-8674(00)81444-0 (Pubitemid 28257589)
40. Kanda K., Nishi K., Kadota A., Nishimoto S., Liu M. C., Sugahara T., Nobiletin suppresses adipocyte differentiation of 3T3-L1 cells by an insulin and IBMX mixture induction. Biochimica et Biophysica Acta 2011 1820 4 461 468
41. Chattopadhyay S., Bhattacharyya S., Saha B., Chakraborthy J., Mohanty S., Sakib Hossain D. M., Banerjee S., Das K., Sa G., Das T., Tumor-shed PGE2 impairs IL2R γ c-signaling to inhibit CD4+ T cell survival: regulation by theaflavins. PLoS ONE 2009 4 10 2-s2.0-70350228294 10.1371/journal.pone.0007382 e7382
42. Singh R. P., Raina K., Deep G., Chan D., Agarwal R., Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clinical Cancer Research 2009 15 2 613 621 2-s2.0-59449097284 10.1158/1078-0432.CCR-08-1846
43. Pandey M. K., Sung B., Ahn K. S., Aggarwal B. B., Butein suppresses constitutive and inducible signal transducer and activator of transcription (stat) 3 activation and stat3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Molecular Pharmacology 2009 75 3 525 533 2-s2.0-62149113324 10.1124/mol.108.052548
44. Nadeau K., Hwa V., Rosenfeld R. G., STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. Journal of Pediatrics 2011 158 5 701 708 2-s2.0-79954419918 10.1016/j.jpeds.2010.12.042
45. Scaglia P. A., Martinez A. S., Feigerlova E., A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease. The Journal of Clinical Endocrinology & Metabolism 2012 97 E830 E839
46. Rotwein P., Mapping the growth hormoneStat5bIGF-I transcriptional circuit. Trends in Endocrinology & Metabolism 2012 23 186 193
47. Han X., Osuntokun B., Benight N., Loesch K., Frank S. J., Denson L. A., Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis. American Journal of Pathology 2006 169 6 1999 2013 2-s2.0-35648986090 10.2353/ajpath.2006.060186 (Pubitemid 351181961)
48. Han X., Ren X., Jurickova I., Groschwitz K., Pasternak B. A., Xu H., Wilson T. A., Hogan S. P., Denson L. A., Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut 2009 58 1 49 58 2-s2.0-58249085437 10.1136/gut.2007.145094
49. Du W., Wang Y. C., Hong J., STAT5 isoforms regulate colorectal cancer cell apoptosis via reduction of mitochondrial membrane potential and generation of reactive oxygen species. Journal of Cellular Physiology 2012 227 2421 2429
50. Garcia R., Bowman T. L., Niu G., Yu H., Minton S., Muro-Cacho C. A., Cox C. E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R., Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001 20 20 2499 2513 2-s2.0-0035799531 10.1038/sj.onc.1204349 (Pubitemid 32531347)
51. Garcia R., Yu C. L., Hudnall A., Catlett R., Nelson K. L., Smithgall T., Fujita D. J., Ethier S. P., Jove R., Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth and Differentiation 1997 8 12 1267 1276 2-s2.0-0031443156 (Pubitemid 28008723)
52. Yamashita H., Iwase H., Toyama T., Fujii Y., Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 2003 22 11 1638 1652 2-s2.0-0037457078 10.1038/sj.onc.1206277 (Pubitemid 36408179)
53. Tan S. H., Nevalainen M. T., Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocrine-Related Cancer 2008 15 2 367 390 2-s2.0-45849116295 10.1677/ERC-08-0013 (Pubitemid 351880829)
54. Yamashita H., Iwase H., The role of Stat5 in estrogen receptor-positive breast cancer. Breast Cancer 2002 9 4 312 318 2-s2.0-0036357646
55. Frasor J., Barkai U., Zhong L., Fazleabas A. T., Gibori G., PRL-induced ER α gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase. Molecular Endocrinology 2001 15 11 1941 1952 2-s2.0-0034740062 10.1210/me.15.11.1941 (Pubitemid 33022533)
56. Frasor J., Gibori G., Prolactin regulation of estrogen receptor expression. Trends in Endocrinology & Metabolism 2003 14 3 118 123 2-s2.0-0038070057 10.1016/S1043-2760(03)00030-4 (Pubitemid 36733909)
57. Peck A. R., Witkiewicz A. K., Liu C., Stringer G. A., Klimowicz A. C., Pequignot E., Freydin B., Tran T. H., Yang N., Rosenberg A. L., Hooke J. A., Kovatich A. J., Nevalainen M. T., Shriver C. D., Hyslop T., Sauter G., Rimm D. L., Magliocco A. M., Rui H., Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Journal of Clinical Oncology 2011 29 18 2448 2458 2-s2.0-79959309120 10.1200/JCO.2010.30.3552
58. Perotti C., Liu R., Parusel C. T., Böcher N., Schultz J., Bork P., Pfitzner E., Groner B., Shemanko C. S., Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Research 2008 10 6, article R94 2-s2.0-63849316576 10.1186/bcr2193
59. Hai T. W., Liu F., Coukos W. J., Green M. R., Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes and Development 1989 3 12 2083 2090 2-s2.0-0024817131 (Pubitemid 20023233)
60. Benbrook D. M., Jones N. C., Heterodimer formation between CREB and JUN proteins. Oncogene 1990 5 3 295 302 2-s2.0-0025276217
61. Bhoumik A., Ronai Z., ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 2008 7 15 2341 2345 2-s2.0-48849111311
62. Recio J. A., Merlino G., Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002 21 7 1000 1008 2-s2.0-0037034199 10.1038/sj/onc/1205150 (Pubitemid 34174512)
63. Takasawa S., Ikeda T., Akiyama T., Nata K., Nakagawa K., Shervani N. J., Noguchi N., Murakami-Kawaguchi S., Yamauchi A., Takahashi I., Tomioka-Kumagai T., Okamoto H., Cyclin D1 activation through ATF-2 in Reg-induced pancreatic β -cell regeneration. FEBS Letters 2006 580 2 585 591 2-s2.0-30644464050 10.1016/j.febslet.2005.12.070 (Pubitemid 43089690)
64. Rubach M., Lang R., Seebach E., Somoza M. M., Hofmann T., Somoza V., Multi-parametric approach to identify coffee components that regulate mechanisms of gastric acid secretion. Molecular Nutrition & Food Research 2012 56 325 335
65. Mujtaba T., Dou Q. P., Black tea polyphenols inhibit tumor proteasome activity. In Vivo 2012 26 197 202
66. Shen M., Chan T. H., Dou Q. P., Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anti-Cancer Agents in Medicinal Chemistry. In press
67. Xue L., Firestone G. L., Bjeldanes L. F., DIM stimulates IFN γ gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 2005 24 14 2343 2353 2-s2.0-16444364134 10.1038/sj.onc.1208434 (Pubitemid 40546693)
68. Kole L., Giri B., Manna S. K., Pal B., Ghosh S., Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NF κ B nuclear translocation. European Journal of Pharmacology 2011 653 13 8 15 2-s2.0-78651505391 10.1016/j.ejphar.2010.11.026
69. Ip Y. T., Davis R. J., Signal transduction by the c-Jun N-terminal kinase (JNK)from inflammation to development. Current Opinion in Cell Biology 1998 10 2 205 219 2-s2.0-0032054723 10.1016/S0955-0674(98)80143-9 (Pubitemid 28174763)
70. Romier B., Schneider Y. J., Larondelle Y., During A., Dietary polyphenols can modulate the intestinal inflammatory response. Nutrition Reviews 2009 67 7 363 378 2-s2.0-70349562760 10.1111/j.1753-4887.2009.00210.x
71. Hollenbach E., Vieth M., Roessner A., Neumann M., Malfertheiner P., Naumann M., Inhibition of RICK/nuclear factor- κ B and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. The Journal of Biological Chemistry 2005 280 15 14981 14988 2-s2.0-17644405863 10.1074/jbc.M500966200 (Pubitemid 40562850)
72. Derer S., Waetzig G. H., Seegert D., Nikolaus S., Schreiber S., Rosenstiel P., A possible link between TIMP-1 induction and response to infliximab. Gut 2009 58 6 888 889 2-s2.0-66649086498 10.1136/gut.2008.167296
73. Mao Y., Li Z., Lou C., Zhang Y., Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma. International Journal of Colorectal Disease 2011 26 1 29 35 2-s2.0-78751591699 10.1007/s00384-010-1090-7
74. Belt E. J., Brosens R. P., Delis-van Diemen P. M., Cell cycle proteins predict recurrence in stage II and III colon cancer. Annals of Surgical Oncology. In press
75. Wangefjord S., Manjer J., Gaber A., Nodin B., Eberhard J., Jirstrom K., Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biology of Sex Differences 2011 2, article 10
76. Hsu C. P., Shih Y. T., Lin B. R., Chiu C. F., Lin C. C., Inhibitory effect and mechanisms of an anthocyanins- and anthocyanidins-rich extract from purple-shoot tea on colorectal carcinoma cell proliferation. Journal of Agricultural and Food Chemistry 2012 60 3686 3692
77. Turktekin M., Konac E., Onen H. I., Alp E., Yilmaz A., Menevse S., Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). Journal of Medicinal Food 2011 14 1107 1117
78. Lim D. Y., Jeong Y., Tyner A. L., Park J. H., Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. American Journal of Physiology 2007 292 1 G66 G75 2-s2.0-33846179993 10.1152/ajpgi.00248.2006 (Pubitemid 46090252)
79. Seelinger G., Merfort I., Wölfle U., Schempp C. M., Anti-carcinogenic effects of the flavonoid luteolin. Molecules 2008 13 10 2628 2651 2-s2.0-55249085887 10.3390/molecules13102628
80. Suh Y., Afaq F., Johnson J. J., Mukhtar H., A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF- κ B-signaling pathways. Carcinogenesis 2009 30 2 300 307 2-s2.0-60149112516 10.1093/carcin/bgn269
81. Zukerberg L. R., Yang W. I., Gadd M., Thor A. D., Koerner F. C., Schmidt E. V., Arnold A., Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Modern Pathology 1995 8 5 560 567 2-s2.0-0029025644
82. Weinstat-Saslow D., Merino M. J., Manrow R. E., Lawrence J. A., Bluth R. F., Wittenbel K. D., Simpson J. F., Page D. L., Steeg P. S., Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Medicine 1995 1 12 1257 1260 2-s2.0-0028845863
83. Simpson J. F., Quan D. E., O'Malley F., Odom-Maryon T., Clarke P. E., Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. American Journal of Pathology 1997 151 1 161 168 2-s2.0-0030785841 (Pubitemid 27283968)
84. Hsiang C. H., Straus D. S., Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 2002 21 14 2212 2226 2-s2.0-0037192632 10.1038/sj.onc.1205293 (Pubitemid 34311375)
85. Sawatsri S., Samid D., Malkapuram S., Sidell N., Inhibition of estrogen-dependent breast cell responses with phenylacetate. International Journal of Cancer 2001 93 5 687 692 2-s2.0-0035452346 10.1002/ijc.1399 (Pubitemid 32695117)
86. Sauter E. R., Nesbit M., Litwin S., Klein-Szanto A. J., Cheffetz S., Herlyn M., Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Research 1999 59 19 4876 4881 2-s2.0-0033215232 (Pubitemid 29472891)
87. Arber N., Doki Y., Han E. K., Sgambato A., Zhou P., Kim N. H., Delohery T., Klein M. G., Holt P. R., Weinstein I. B., Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Research 1997 57 8 1569 1574 2-s2.0-0030949419 (Pubitemid 27175576)
88. Kornmann M., Arber N., Korc M., Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. The Journal of Clinical Investigation 1998 101 2 344 352 2-s2.0-0032518616 (Pubitemid 28067331)
89. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P. J., Pestell R., Albanese C., Sausville E. A., Senderowicz A. M., Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Research 1999 59 18 4634 4641 2-s2.0-0033568521 (Pubitemid 29428969)